Shopping Cart
- Remove All
Your shopping cart is currently empty
ACY-775 is an effective and specific inhibitor of HDAC6 (IC50: 7.5 nM).

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $43 | In Stock | |
| 10 mg | $73 | In Stock | |
| 25 mg | $153 | In Stock | |
| 50 mg | $248 | In Stock | |
| 100 mg | $371 | In Stock | |
| 200 mg | $527 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $47 | In Stock |
| Description | ACY-775 is an effective and specific inhibitor of HDAC6 (IC50: 7.5 nM). |
| Targets&IC50 | HDAC6:7.5 nM, HDAC3:11223 nM, HDAC1:2123 nM, HDAC2:2570 nM |
| In vitro | Upon treatment with ACY-775, a clear enhancement of the acetylation of α-tubulin is visible, while histone acetylation remains unaltered. Acetylation of α-tubulin is visualized by immunofluorescence and the intensity in the neurites of the neurons is quantified and normalized to the length of the fluorescent signal. In vehicle-treated DRG neurons, acetylated α-tubulin is already present. Upon treatment with ACY-775, the signal intensity of acetylated α-tubulin increases significantly. A significant increase in motility of mitochondria and also the total number of mitochondria within the neurites are observed compared with vehicle-treated DRG neurons. A significantly higher number of retrogradely transport mitochondria is observed in DRG neurons treated with ACY-775 compared with vehicle-treated cells [1]. |
| In vivo | Biodistribution profiles of ACY-775 are examined after acute dosing at 5 or 50?mg/kg over 2?h. At t=30?min after acute 50?mg/kg injection, respective plasma levels of ACY-775 is 1359?ng/mL (4.1?μM). Elimination from the plasma is rapid, with a plasmatic half-life of 12?min and a concentration below 10?ng/mL after 2?h. When ACY-775 (50?mg/kg) is administered repeatedly in wild-type mice at 24?h, 4?h, and 30?min before killing, significant increases in α-tubulin acetylation are observed in all tested brain regions [2]. |
| Cell Research | Undifferentiated RN46A-B14 cells are grown. They are treated with 2.5?μM ACY-738, ACY-775, tubastatin A, 0.6?μM TSA or vehicle (0.1% DMSO) for 4?h. Samples are processed using a histone extraction kit and quantified using protein assay [2]. |
| Animal Research | Mice are tested for immobility in the TST. At 30?min or 2?h after i.p. injection of ACY-738 (5, 50?mg/kg), ACY-775 (5, 50?mg/kg), and citalopram (0.5, 2, 20?mg/kg), a combination of the previous, or vehicle, mice are attached to the test rig and time immobile over 6?min is recorded. For open-field activity, mice are injected with ACY-738 or ACY-775 at 5, 10, or 50?mg/kg or vehicle and allowed to explore [2]. |
| Molecular Weight | 330.36 |
| Formula | C17H19FN4O2 |
| Cas No. | 1375466-18-4 |
| Smiles | ONC(=O)c1cnc(NC2(CCCCC2)c2cccc(F)c2)nc1 |
| Relative Density. | 1.342 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (302.70 mM), Sonication and heating are recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (12.11 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.